Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin

by NASDAQ Market News July 28, 2020

NASDAQ Market News
Click here to email author

Aegea Biotechnologies, Inc. and Tauriga Sciences Inc. Announce Progress on the Development of Rapid, Lateral Flow Point-of-Care COVID-19 Diagnostic Test

Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide

Ads